Drug firm Granules India on Tuesday said it will take some time to shift API (Active Pharmaceutical Ingredient) volumes from China to India.
In an interview to CNBC-TV18, Krishna Prasad Chigurupati, chairman and managing director, said, "Most of our customers today wants to know where the API is coming from. They want to know our entire supply chain and if the API is coming from the Indian manufacturers and especially if it is coming from our own facilities, we are given a preference. So this is really going to help."
Prasad welcomed government's Production-Linked Incentive (PLI) scheme and said it's going to help a lot of APIs to be made in India. However, he said interest is not as strong as anticipated.
"As Granules, we were not interested in PLI scheme. We did not want to participate as we wanted to do something on a larger scale for some of the APIs and the PLI scheme is not conducive. Overall, I am quite excited and happy that there has been a decent response and it is going to help lot of API small manufacturers in the company," he said.To know more, watch this video.